Patent application number | Description | Published |
20110032797 | Magnetic mass-lift impulsive seismic energy source including attracting and repulsing electromagnets - A seismic energy source includes a base plate and a block fixedly coupled in a frame. The base plate is configured for contact with a part of the Earth's subsurface to be seismically energized. The frame has a first electromagnet associated therewith. A second electromagnet is disposed in a travelling reaction mass, which is movably disposed in the frame between the first electromagnet assembly and the top block. The reaction mass includes at least a third electromagnet associated therewith. The source has circuits for selectively energizing the first, second and at least a third electromagnets, and which are configured to energize the first and second electromagnets to repel each other such that the traveling reaction mass is lifted from the first electromagnet, and configured to energize the at least a third electromagnet after a selected delay time to cause attraction between the traveling reaction mass and the top block | 02-10-2011 |
20110139537 | Magnetic mass-lift impulsive seismic energy source including repelling electromagnets and reaction mass damping - A seismic energy source includes a base plate having a first electromagnet thereon. A reaction mass has a second electromagnet thereon. A switchable current source is connected to the first and second electromagnets such that the first electromagnet repels the second electromagnet. At least one damper is functionally connected between the reaction mass and the base plate. The damper is configured to enable faster movement of the reaction mass away from the base plate than toward the base plate. | 06-16-2011 |
20120269032 | Magnetic Mass-Lift Impulsive Seismic Energy Source Including Attracting and Repulsing Electromagnets - A seismic energy source includes a base plate and a block fixedly coupled in a frame. The base plate is configured for contact with a part of the Earth's subsurface to be seismically energized. The frame has a first electromagnet associated therewith. A second electromagnet is disposed in a travelling reaction mass, which is movably disposed in the frame between the first electromagnet assembly and the top block. The reaction mass includes at least a third electromagnet associated therewith. The source has circuits for selectively energizing the first, second and at least a third electromagnets, and which are configured to energize the first and second electromagnets to repel each other such that the traveling reaction mass is lifted from the first electromagnet, and configured to energize the at least a third electromagnet after a selected delay time to cause attraction between the traveling reaction mass and the top block | 10-25-2012 |
Patent application number | Description | Published |
20090253625 | GLP-1, exendin-4, peptide analogs and uses thereof - The invention relates to novel polypeptide analogues of GLP-1 and exendin-4. The polypeptide, in a preferred embodiment, is insulinotropic and long-acting. Preferably, the polypeptide's insulinotropic effect is comparable to or exceeds the effect of an equimolar amount of GLP-1 or exendin-4. The invention also relates to a method of treating a subject with diabetes, comprising administering to the subject the polypeptide of the invention in an amount that has an insulinotropic effect. The invention also relates to methods of using GLP-1, exendin-4, and polypeptide analogues thereof for neuroprotective and neurotrophic effects. | 10-08-2009 |
20120329715 | GLP-1, EXENDIN-4, PEPTIDE ANALOGS AND USES THEREOF - The invention relates to novel polypeptide analogues of GLP-1 and exendin-4. The polypeptide, in a preferred embodiment, is insulinotropic and long-acting. Preferably, the polypeptide's insulinotropic effect is comparable to or exceeds the effect of an equimolar amount of GLP-1 or exendin-4. The invention also relates to a method of treating a subject with diabetes, comprising administering to the subject the polypeptide of the invention in an amount that has an insulinotropic effect. The invention also relates to methods of using GLP-1, exendin-4, and polypeptide analogues thereof for neuroprotective and neurotrophic effects. | 12-27-2012 |
Patent application number | Description | Published |
20080319032 | TETRAHYDROBENZOTHIAZOLE ANALOGUES AS NEUROPROTECTIVE AGENTS - This invention relates generally to tetrahydrobenzothiazole analogues and tetrahydrobenzooxyzole analogues, to pharmaceutical compositions which include these compounds and a pharmaceutically acceptable carrier, and to methods of treatment using these compounds. The invention also encompasses pharmaceutically acceptable esters, amides, and salts of such compounds. The invention further provides a method of reducing or delaying apoptosis in a population of cells, comprising contacting the population of cells with a tetrahydrobenzothiazole analogue or a tetrahydrobenzooxyzole analogue, thereby reducing or delaying apoptosis in the population of cells. | 12-25-2008 |
20090131501 | Agents Useful for Reducing Amyloid Precursor Protein and Treating Dementia and Methods of Use Thereof - The present invention provides compounds and methods of administering compounds to a subject that can reduce βAPP production and that is not toxic in a wide range of dosages. The present invention also provides non-carbamate compounds and methods of administering such compounds to a subject that can reduce βAPP production and that is not toxic in a wide range of dosages. It has been discovered that either the racemic or enantiomerically pure non-carbamate compounds can be used to decrease βAPP production. | 05-21-2009 |
20100105707 | METHOD OF TREATING OR PREVENTING OXIDATIVE STRESS-RELATED DISEASE - Disclosed is a method of treating or preventing an oxidative stress-related disease in a mammal in need thereof comprising administering an effective amount of a compound of formula (I) to the mammal, wherein R | 04-29-2010 |
20100144704 | Method of reducing amyloid-beta peptide levels using a bisdioxopiperazine - Disclosed are methods of reducing amyloid-β peptide levels in a subject. The method involves administering to the subject a therapeutically effective amount of a bisdioxopiperazine or a pharmaceutically acceptable salt thereof to reduce β-amyloid peptide levels. | 06-10-2010 |
20110021594 | Agents Useful for Reducing Amyloid Precursor Protein and Treating Dementia and Methods of Use Thereof - The present invention provides compounds and methods of administering compounds to a subject that can reduce βAPP production and that is not toxic in a wide range of dosages. The present invention also provides non-carbamate compounds and methods of administering such compounds to a subject that can reduce βAPP production and that is not toxic in a wide range of dosages. It has been discovered that either the racemic or enantiomerically pure non-carbamate compounds can be used to decrease βAPP production. | 01-27-2011 |
20110245210 | THALIDOMIDE ANALOGS - Thalidomide analogs that modulate tumor necrosis factor alpha (TNF-α) activity and angiogenesis are disclosed. In particularly disclosed embodiments, the thalidomide analogs are isosteric sulfur-containing analogs. Also disclosed are methods of treating a subject with the analogs. | 10-06-2011 |
20120295946 | Agents Useful for Reducing Amyloid Precursor Protein and Treating Dementia and Methods of Use Thereof - The present invention provides compounds and methods of administering compounds to a subject that can reduce βAPP production and that is not toxic in a wide range of dosages. The present invention also provides non-carbamate compounds and methods of administering such compounds to a subject that can reduce βAPP production and that is not toxic in a wide range of dosages. It has been discovered that either the racemic or enantiomerically pure non-carbamate compounds can be used to decrease βAPP production. | 11-22-2012 |
20130035363 | Thalidomide Analogs - Thalidomide analogs that modulate tumor necrosis factor alpha (TNFα) activity and angiogenesis are disclosed. In particularly disclosed embodiments, the thalidomide analogs are isosteric sulfur-containing analogs. Also disclosed are methods of treating a subject with the analogs. | 02-07-2013 |
20130143922 | THIO COMPOUNDS - A compound, or a pharmaceutically acceptable salt or ester thereof, having a structure of: | 06-06-2013 |
20140309436 | THALIDOMIDE ANALOGS - Thalidomide analogs that modulate tumor necrosis factor alpha (TNFα) activity and angiogenesis are disclosed. In particularly disclosed embodiments, the thalidomide analogs are isosteric sulfur-containing analogs. Also disclosed are methods of treating a subject with the analogs. | 10-16-2014 |
20150072930 | GLP-1, EXENDIN-4, PEPTIDE ANALOGS AND USES THEREOF - The invention relates to novel polypeptide analogs of GLP-1 and exendin-4. The polypeptide, in a preferred embodiment, is insulinotropic and long-acting. Preferably, the polypeptide's insulinotropic effect is comparable to or exceeds the effect of an equimolar amount of GLP-1 or exendin-4. The invention also relates to a method of treating a subject with diabetes, comprising administering to the subject the polypeptide of the invention in an amount that has an insulinotropic effect. The invention also relates to methods of using GLP-1, exendin-4, and polypeptide analogs thereof for neuroprotective and neurotrophic effects. | 03-12-2015 |
20150359784 | THIO COMPOUNDS - A compound, or a pharmaceutically acceptable salt or ester thereof, having a structure of: | 12-17-2015 |
Patent application number | Description | Published |
20090157543 | Systems And Methods For Loan Option Customization - In a loan option system having a loan server accessible through a network to an external borrower computer and a loan processor for providing loan parameters to the loan server, systems and methods are provided for determining and adjusting a loan balance, via (1) receiving a principal value for a loan through the network from the borrower computer, the principal value corresponding to the loan balance, wherein the loan has an interest rate and a loan term corresponding to a specified number of payments throughout the loan, (2) upon a permissible omitted payment, increasing the interest rate, determining accrued interest, setting predetermined fees due to the missed payment, and applying the predetermined fees and accrued interest to the loan balance to produce a new balance, (3) retrieving the new balance from the loan processor to the loan server, and (4) providing the new balance to the borrower computer. | 06-18-2009 |
20140122322 | Loan Option Customization - In a loan option system having a loan server accessible through a network to an external borrower computer and a loan processor for providing loan parameters to the loan server, systems and methods are provided for determining and adjusting a loan balance, via (1) receiving a principal value for a loan through the network from the borrower computer, the principal value corresponding to the loan balance, wherein the loan has an interest rate and a loan term corresponding to a specified number of payments throughout the loan, (2) upon a permissible omitted payment, increasing the interest rate, determining accrued interest, setting predetermined fees due to the missed payment, and applying the predetermined fees and accrued interest to the loan balance to produce a new balance, (3) retrieving the new balance from the loan processor to the loan server, and (4) providing the new balance to the borrower computer. | 05-01-2014 |